We retrospectively analyzed 65 patients with refractory/relapsed (r/r) ALL who were treated with blinatumomab for predictors of leukemia response as well as clinical patterns of relapse and resistance with particular focus on downregulation of CD19 expression and extramedullary disease (EM-ALL). The complete remission (CR) rate was 51%, and 15 (45%) responders underwent allogeneic hematopoietic cell transplantation (HCT) in CR. High leukemia burden (bone marrow blasts >50%) (P 5 .02), history of prior EM-ALL (P 5 .005), and active EM-ALL at the time of initiating blinatumomab (P 5 .05) predicted lower CR rate. Among refractory cases, 13 (41%) had evidence of EM-ALL progression, and CD19 expression was negative or dim in 18% and 23%, respectively.
| I N T R O D U C T I O N
The CD19/CD3 bispecific T-cell engager antibody (BiTE) blinatumomab redirects autologous CD3-positive T-cells to CD19-positive acute lymphoblastic leukemia (ALL) cells thereby creating a cytolytic synapse leading to lysis of malignant cells. Blinatumomab has notable single agent activity in relapsed/refractory (r/r) acute lymphoblastic leukemia, 1, 2 and it has shown superiority when compared to physician's choice of combination chemotherapies in a phase III randomized trial. 3 Despite the encouraging complete remission (CR) rate in r/r ALL, over half of treated patients fail to achieve meaningful response with blinatumomab and relapses are common with continued therapy for overt disease. 1, 3 Previous observations have concluded that blinatumomab therapy produces higher response rate in patients with lower disease burden, and an association of response with lower bone marrow regulatory T-cells has been observed. 1, 4 The patterns of disease relapse as well as mechanisms of leukemia escape from blinatumomab effect remain poorly characterized. Relapse of disease at extramedullary (EM) sites as well as loss of CD19 antigen expression are potential mechanisms of resistance following blinatumomab therapy, and there were reported at the time of ALL progression or relapse following treatment. 2, 5 Here, we characterize in detail the clinical patterns of resistance and relapses following blinatumomab therapy, with special emphasis on the occurrence of EM-ALL and examine CD19 expression on leukemia blasts at the time of blinatumomab failure.
| Patient population
We retrospectively reviewed all cases of r/r precursor B-cell ALL treated with blinatumomab at City of Hope Medical Center between 05/2012 and 07/2016. We excluded cases where blinatumomab was administered for untreated ALL or patients treated in morphological remission but with minimal residual disease (MRD). We also excluded cases that had no response assessment due to death before completion of a single cycle of blinatumomab. Patient characteristics, prior treatment and leukemia characteristics were reviewed in detail, and we analyzed leukemia phenotype as well as sites of disease involvement before and after blinatumomab therapy. We also collected data on the occurrence of cytokine-release syndrome (CRS), neurotoxicity, the use and duration of corticosteroid therapy as well as the peak of C-reactive protein (CRP) during first cycle. The severity of CRS was graded as described previously. 6 The study was approved by the Institutional Review Board (IRB).
| Flow cytometric analysis
Bone marrow and peripheral blood specimens were stained within 24 h of collection with a panel of antibodies including CD19, CD34, and CD10
(Beckman Coulter) and analyzed using 8 color Beckman Coulter Canto II.
Data were analyzed with Kaluza Flow Cytometry Analysis Software 1.3
(Beckman Coulter, IN). Determination of CD19 expression was compared to normal B lymphocytes in the CD45 bright region (lymphocyte gate). In addition, geometric mean fluorescence intensity (MFI) was also determined for CD19 for each lymphoblast population. Reviewing analysis was performed by a single hematopathologist (J.S.).
| Statistical analysis
Demographics, disease, and treatment characteristics for all patients were summarized using descriptive statistics. Relationships between categorical variables of interest were assessed using chi-square tests. Logistic regression was used to determine predictors of response to blinatumomab, EM-ALL relapse/progression, and loss of CD19 expression after blinatumomab therapy. Differences in CD19 expression pre-and postblinatumomab, days of corticosteroid use, and peak CRP by response to blinatumomab were evaluated using t tests. Overall survival (OS) and event-free survival (EFS) were calculated using the Kaplan-Meier product limit method, 7 and confidence intervals were calculated using the logit transformation and the Greenwood variance estimate. 8 Cox proportional hazards models were used to determine predictors of OS. All calculations were performed using SAS 9.4 (SAS Institute, Cary, NC).
| R E S U LTS

| Patient characteristics
We identified 65 evaluable patients with r/r ALL who were treated with blinatumomab. Six patients received blinatumomab for r/r ALL were excluded from the analysis due to morphological remission but persistent MRD at the time of stating therapy (N 5 4) and death before completing 28 days of blinatumomab (N 5 2). The median age was 33 years (range: 7-74), and five patients were younger than 18 years of age. Patient demographics are summarized in Table 1 . Table 2 .
High disease burden defined as BM blasts >50% (OR 5 0.24; Therefore, the presence of EM-ALL at the time of initiating treatment is an independent predictor of blinatumomab therapy failure and such patients appear to be poor candidates for blinatumomab. Relapses occur in the majority of responders who are not consolidated with allogeneic HCT.
| Sites of leukemia progression/relapse following blinatumomab therapy
Among responders, the site of subsequent disease relapse was BM only in 12 (60%) patients and extramedullary (EM) site with or without concurrent BM involvement in 8 (40%) patients. Sites of EM relapse included kidney, CNS, lymph node, muscle, chest wall, and nasopharynx.
Among patients refractory to blinatumomab, the site of disease progression was only in the BM in 19 patients (59%), EM site without BM disease in 9 (28%), and concurrent involvement of the BM and EM (6) site in 4 (13%). The most common EM progression site was lymph node (N 5 5), and this was followed by the kidney (N 5 Table 1 .
History of EM-ALL prior to blinatumomab therapy (OR 5 3.46; P 5 .04) as well as higher pretreatment CD19 expression on leukemic blasts (strong/moderate vs. dim) (OR 5 6.40; P 5 .01) were identified as predictors for EM-ALL relapse/progression with or without concurrent BM involvement following blinatumomab therapy (Table 5) .
Therefore, EM-ALL is common at the time of disease progression or relapse following blinatumomab therapy, and prior history of EM-ALL and higher CD19 expression by leukemic blasts predict treatment failure at EM sites.
| Blast CD19 expression at progression/relapse following blinatumomab therapy
In order to determine if loss of CD19 expression was a mechanism for blinatumomab failure, we examined the strength of CD19 expression by flow cytometry on leukemic blasts before and after blinatumomab therapy. Among blinatumomab responders who subsequently relapsed, and expression intensity was graded as negative, dim and moderate/ strong in 6 (35%), 1 (6%), and 10 (59%), respectively. Of 12 patients with subsequent isolated BM relapse after responding to blinatumomab therapy, 5 (42%) had CD19 negative relapse.
For nonresponders, leukemia CD19 expression at the time of progression was available in 22 (69%) cases, in which expression was negative in 4 (18%), dim in 5 (23%), and moderate/strong in 13 (59%). 
respectively. There was no difference in pretreatment CD19 MFI among responders and nonresponders (P 5 .93); however, the reduction in mean geometric CD19 expression (pretreatment vs. posttreatment) was significantly higher among relapsed cases compared to refractory cases (1.26 vs. 0.09; P 5 .04) ( Table 6 ; Supporting Information Figure 1 ).
We compared cytogenetics/FISH data in eight patients with CD19
negative ALL at the time of progression or relapse to available cytogenetic data immediately prior to initiating blinatumomab therapy. Five of eight cases had identical cytogenetics, two had cytogenetic evolution and one case had different cytogenetic abnormalities.
Therefore, loss of CD19 expression is one mechanism for disease relapse/refractoriness following blinatumomab therapy, and we observed more pronounced reduction in CD19 expression at time of relapse in responders compared to refractory cases. Since only a subset of cases had loss of CD19 at relapse/progression other mechanisms must contribute to disease escape from cytotoxicity of blinatumomab.
| Disease-free survival and overall survival
The median follow up for all patients was 6.8 months (0.9-42.7), and for surviving patients was 19. Nonrelapse mortality at 100 days for transplanted patients was 7%.
Grade III/IV acute graft-versus host disease (GVHD) occurred in 3 (20%) cases, and no case of veno-occlusive disease (VOD) noted.
Causes of death among responders and reasons for not proceeding with allogeneic HCT are listed in Table 1 .
Thus, survival was better for patients who responded to blinatumomab compared to those who did not, and consolidation with allogeneic HCT is required for long term remission following response to blinatumomab therapy in r/r ALL. 
| Blinatumomab toxicity and disease response
The occurrence of CRS of any grade was very common during the first cycle of blinatumomab therapy, but the majority were only grade 1 in severity. There was no statistical difference in the incidence of CRS between responders and nonresponders to blinatumomab (76% vs.
59% respectively, P 5 .16). However, when we restricted the analysis to CRS of grade 2 severity only, there was a higher incidence in responders compared to nonresponders (33% vs. 9% respectively, 
| DISCUSSION
In this paper, we present a detailed analysis of outcomes of blinatumomab therapy at our institution particularly highlighting patterns of treatment failure, with special emphasis on EM-ALL and CD19 expression. We show for the first time that prior history EM-ALL as well as evidence of EM-ALL at the time of blinatumomab therapy confer increased risk of resistance to blinatumomab therapy. Our observations may provide some guidance which patient should be treated with blinatumomab when there are other potential options for patients with r/r ALL. We have shown that roughly half of our r/r ALL patients achieved CR with blinatumomab therapy, which is consistent with results of previous studies of this agent. 1,3 Moreover, we observed improved response to blinatumomab in patients with lower disease burden which is again similar to previous reports. 1 The observation that lower disease burden improves response also provides a rationale for using targeted chemotherapeutic or immunotherapeutic approaches to achieve cytor- The most effective use of blinatumomab appears to be as a bridge to allogeneic HCT in patients who are suitable candidates. Allogeneic
HCT was essential to assure prolonged remission after response to blinatumomab and without such consolidation relapse occurred in the majority of patients. Early relapse after initial response to blinatumomab was the main hurdle that prevented responders from receiving allogeneic HCT consolidation. Nonetheless, the NRM after allogeneic HCT was low, and blinatumomab does not appear to have any excessive toxicity that impacts subsequent allogeneic HCT. In some of our patients blinatumomab was used to treat relapse after previous allogeneic HCT. We did note one such patient who enjoyed a long-term remission with blinatumomab without subsequent allogeneic HCT consolidation. We postulate that graft versus leukemia potentially maintained his remission. Individual case reports have described similar sustained remissions in ALL patients who have relapsed after allogeneic HCT and were treated with blinatumomab. 13 We examined in detail whether blinatumomab is effective in patients who had EM-ALL and if EM-ALL at time of therapy precluded response. Our data show that ALL progression at EM sites is common in nonresponders and can be encountered even when remission is attained in the bone marrow. Likewise, we observed that among blinatumomab responders who subsequently relapsed there was a high rate of EM-ALL suggesting that the drug is not effective in eradicating disease from EM sites at the doses currently used. Furthermore, prior history of EM-ALL predicted EM-ALL involvement at relapse or pro- It is unclear why higher CD19 expression prior to therapy was associated with occurrence of EM-ALL.
Another interesting observation with blinatumomab therapy is the change in CD19 expression on leukemic blasts following therapy, a phenomenon that has been reported with other CD19-targeted immunotherapies as well. 2, 5 Loss of CD19 expression following blinatumomab was mentioned briefly in prior reports, but our series is the first to study this phenomenon comprehensively. CD19-negative ALL relapse was more common for patients who responded to blinatumomab and subsequently relapsed, and it occurred in almost 40% of such cases, and was more common when treatment failure was in the BM. This could be related to downregulation of CD19 receptors after exposure to blinatumomab or expansion of pre-existing small CD19-negative clones. Interestingly, recent report examining four cases of CD19-relapsed ALL following blinatumomab therapy showed preservation of leukemic phenotype with the exception of CD19 expression, and in one case, molecular analysis implicated the disruption of CD19 trafficking in the post endoplasmic reticulum system as a reason of CD19 expression loss. 15 We show here that in the majority of cases when treatment failure following blinatumomab was manifested as CD19 negative ALL, however, the cytogenetic profile was identical to the original clone suggesting acquisition of genetic or epigenetic alterations in the original leukemia clone that leads to loss of CD19 antigen expression. Disrupted membrane export of CD19 was shown in a recently reported cases and could be a mechanism for loss of CD19 expression on cell surface. 15 Other mechanisms of CD19 expression loss have been described following CD19-based CAR-T cell therapy and include mutations in the CD19 gene as well as alternate splicing of CD19 mRNA leading to surface expression of truncated CD19
variants. 16 We did not see any difference in pretreatment CD19 expression between responders and nonresponders, but there was more pronounced reduction in CD19 expression among initial responders who relapsed compared to refractory cases, and this observation may have implications for future CD19-targeted therapy options like CD19 CAR T-cells for this population upon relapse.
We could not identify any risk factors for treatment failure with CD19-negative disease in our analysis.
We show that although CRS was common during blinatumomab therapy, the majority of these events were mild and manifested only as fever. CRS of Grade 2 severity was more common among responders compared to non-responders but CRS severity did not correlate with survival or disease burden. An association between disease burden and CRS has been observed with CAR-T cell therapy. 17, 18 One explanation why higher disease burden was not associated with an increased incidence of CRS in our cohort could be due to the more liberal use of corticosteroids in cases with higher disease burden, likely because the treating physician anticipated a higher CRS in this population. Corticosteroid use during blinatumomab therapy was very common in our cohort and more common in patients with higher disease burden. However, similar to prior preclinical and clinical data, 1,19 dexamethasone use did not impair response in our cohort.
In conclusion, although around half of r/r ALL treated with blinatumomab achieve remission, relapses are common during therapy and often preclude consolidation with allogeneic HCT. In addition to high tumor burden, concurrent as well as prior history of EM-ALL are associated with lower response to blinatumomab. Both EM-ALL and CD19-negative disease are common during blinatumomab failure in r/r ALL.
Extramedullary disease progression can occur during blinatumomab therapy even when remission is attained in the BM. Higher pretreatment CD19 expression as well as prior history of EM-ALL were associated with EM involvement at the time of blinatumomab failure.
With the development of multiple effective immune based therapies including CAR-modified T-cells and the CD22 immunoconjugate inotuzumab, sequencing these treatments for r/r ALL becomes especially important. Based on our data, blinatumomab appears to be a poor choice for patients with history of or concurrent EM-ALL involvement.
Loss of CD19 expression should be considered while choosing an immunotherapy option after failure of blinatumomab. The efficacy of other immune based therapies for r/r ALL in EM-ALL needs to be further evaluated and it remains to be determined if higher doses of blinatumomab can decrease relapse/progression at extramedullary sites.
